Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

Area of Science:

• Pediatric Immunology
• Infectious Diseases
• Virology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initially appeared to spare children from severe illness.
• A novel multisystem inflammatory syndrome in children (MIS-C) emerged during the COVID-19 pandemic.
• Understanding the immune response in MIS-C is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the immune profiles of children diagnosed with MIS-C.
• To identify specific inflammatory markers, immune cell changes, and autoantibody reactivities associated with MIS-C.
• To evaluate the efficacy of anti-IL-6R antibody and intravenous immunoglobulin (IVIG) in treating MIS-C.

Main Methods:

• Analysis of immune profiles in nine MIS-C patients.
• Cytokine profiling to assess inflammatory signatures.
• Immunophenotyping of peripheral blood to analyze immune cell populations.
• Autoantigen reactivity profiling of patient plasma.

Main Results:

• All MIS-C patients had evidence of prior SARS-CoV-2 infection with a neutralizing antibody response.
• Elevated levels of IL-18, IL-6, CCL3, CCL4, CDCP1, IL-17A, CCL20, and CCL28 were observed.
• Reductions in non-classical monocytes and specific NK and T lymphocyte subsets were noted.
• Autoantibodies targeting endothelial, gastrointestinal, and immune cells were identified, including anti-La.

Conclusions:

• MIS-C is characterized by a distinct inflammatory immune signature and autoantibody production following SARS-CoV-2 exposure.
• Therapeutic interventions targeting IL-6 receptor or using IVIG demonstrated rapid clinical improvement in MIS-C patients.
• These findings highlight potential therapeutic strategies and diagnostic markers for MIS-C.